Immunotherapy News and Research

Latest Immunotherapy News and Research

Patient-specific immunotherapeutic vaccines may improve overall survival of melanoma patients

Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.

11 May 2016

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Cancer immunology is all about how your immune cells are going to fight and kill your tumor cells. If you look at the pure genetic code of a T-cell that's going to kill your tumor compared to the same cell that has been “put-to-sleep” (by the tumor), the pure genetic DNA content of those two cells are identical.

From NanoString Technologies 11 May 2016

Study provides vital information regarding four diagnostic PD-L1 assays

A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer, announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research on April 19.

6 May 2016

Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight.

6 May 2016

Duke scientists develop human-derived antibody that preferentially attacks cancer cells

A research team from Duke Health has developed an antibody from the body's own immune system that preferentially attacks cancer cells.

6 May 2016

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

5 May 2016

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial.

4 May 2016

Cerebellar not cerebral atrophy predicts poor anti-NMDAR encephalitis outcome

Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report.

4 May 2016

$Ibrutinib shows added benefit for refractory mantle cell lymphoma patients$

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.

3 May 2016

Addition of L19-IL2 can increase radiation therapy-induced immune response against tumours

Radiation therapy not only kills cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to cure tumours, and even when it is, its effect is limited to the area that has been irradiated.

2 May 2016

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

29 Apr 2016

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers.

28 Apr 2016

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA.

27 Apr 2016

Scientists uncover molecular identity of previously unknown Glima molecule in Type 1 diabetes

Scientists have solved a decades-old medical mystery by finally identifying a previously unknown molecule which is attacked by the immune system in people with Type 1 diabetes.

25 Apr 2016

Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature.

25 Apr 2016

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.

22 Apr 2016

Study paves way for refining antibody-based cancer immunotherapy

A study coordinated by the Malmberg Laboratory at Oslo University Hospital/University of Oslo and the Karolinska Institute, published in Cell Reports, reveals a molecule that trigger cancer recognition in natural killer (NK) cells.

22 Apr 2016

Better way to model human immune system

Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling "dirty mice."

21 Apr 2016

Proteins can be used as targets to deliver drugs into stressed cancer cells

Targeted missiles that can enter cancer cells and deliver lethal cell toxins without harming surrounding healthy tissue. This has been a long-standing vision in cancer research, but it has proved difficult to accomplish. A research group at Lund University in Sweden has now taken some crucial steps in this direction.

20 Apr 2016

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy.

20 Apr 2016

Immunotherapy News and Research

Latest Immunotherapy News and Research

Patient-specific immunotherapeutic vaccines may improve overall survival of melanoma patients

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Study provides vital information regarding four diagnostic PD-L1 assays

Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

Duke scientists develop human-derived antibody that preferentially attacks cancer cells

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

NSCLC MAGE-A3 immunotherapy development halted

Cerebellar not cerebral atrophy predicts poor anti-NMDAR encephalitis outcome

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Addition of L19-IL2 can increase radiation therapy-induced immune response against tumours

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Experimental therapy has over 90% remission rate for advanced leukemia patients

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

Scientists uncover molecular identity of previously unknown Glima molecule in Type 1 diabetes

Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Study paves way for refining antibody-based cancer immunotherapy

Better way to model human immune system

Proteins can be used as targets to deliver drugs into stressed cancer cells

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in